Matt Kaeberlein on Rapamycin Longevity Series | Lessons learned from two decades of Rapamycin research
Master One Thing - Rapamycin Longevity Series
Exploring Rapamycin and mTOR Inhibition
The chapter delves into the efficacy of rapamycin in crossing the blood-brain barrier and inhibiting mTOR complex one activity in the brain, while discussing the need for more research and clinical trials in this field. It also highlights the challenges in funding for aging research and the potential risks associated with the off-label use of rapamycin, particularly in organ transplant patients. The conversation touches on the impact of rapamycin on skin health and appearance, showcasing a study on skin senescence and highlighting the complexities of expecting anti-aging interventions to reverse cosmetic signs of aging.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
